Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Stevens

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Biochemical Pharmacology|October 21, 2021
Respiratory depressant effects of fentanyl analogs are opioid receptor-mediatedNeil B Varshneya, Sherif H Hassanien, Melissa C Holt, et al.
Pharmacology, Biochemistry, and Behavior|May 26, 2023
Fentanyl analog structure-activity relationships demonstrate determinants of diverging potencies for antinociception and respiratory depressionNeil B Varshneya, Sherif H Hassanien, Melissa C Holt, et al.
Journal of Medicinal Chemistry|November 30, 2019
Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor ModulatorsHongguang Ma, Samuel Obeng, Huiqun Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2020
Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populationsSergey V Melnikov, David L Stevens, Xian Fu, et al.
Brain, Behavior, and Immunity|November 18, 2017
CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and rewardMaciej Gonek, Virginia D McLane, David L Stevens, et al.
Bioorganic & Medicinal Chemistry|March 19, 2015
Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligandsYunyun Yuan, Saheem A Zaidi, David L Stevens, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 7, 2015
Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic MiceSylvia Fitting, David L Stevens, Fayez A Khan, et al.
Journal of Medicinal Chemistry|October 23, 2013
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivityYunyun Yuan, Saheem A Zaidi, Orgil Elbegdorj, et al.
ACS Chemical Neuroscience|July 21, 2012
Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonistsYunyun Yuan, Guo Li, Hengjun He, et al.
Journal of Medicinal Chemistry|December 20, 2022
Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG ToxicityHongguang Ma, Piyusha P Pagare, Mengchu Li, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Biochemical Pharmacology|October 21, 2021
Respiratory depressant effects of fentanyl analogs are opioid receptor-mediatedNeil B Varshneya, Sherif H Hassanien, Melissa C Holt, et al.
Pharmacology, Biochemistry, and Behavior|May 26, 2023
Fentanyl analog structure-activity relationships demonstrate determinants of diverging potencies for antinociception and respiratory depressionNeil B Varshneya, Sherif H Hassanien, Melissa C Holt, et al.
Journal of Medicinal Chemistry|November 30, 2019
Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor ModulatorsHongguang Ma, Samuel Obeng, Huiqun Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2020
Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populationsSergey V Melnikov, David L Stevens, Xian Fu, et al.
Brain, Behavior, and Immunity|November 18, 2017
CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and rewardMaciej Gonek, Virginia D McLane, David L Stevens, et al.
Bioorganic & Medicinal Chemistry|March 19, 2015
Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligandsYunyun Yuan, Saheem A Zaidi, David L Stevens, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 7, 2015
Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic MiceSylvia Fitting, David L Stevens, Fayez A Khan, et al.
Journal of Medicinal Chemistry|October 23, 2013
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivityYunyun Yuan, Saheem A Zaidi, Orgil Elbegdorj, et al.
ACS Chemical Neuroscience|July 21, 2012
Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonistsYunyun Yuan, Guo Li, Hengjun He, et al.
Journal of Medicinal Chemistry|December 20, 2022
Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG ToxicityHongguang Ma, Piyusha P Pagare, Mengchu Li, et al.
Pageof 6